XML 28 R17.htm IDEA: XBRL DOCUMENT v3.3.1.900
12. Segments
 9 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
12. Segments

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

 

The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:

 

   Nine Months Ended December 31, 
   2015   2014 
Revenues:          
Aethlon  $681,907   $563,805 
ESI   –    – 
Total Revenues  $681,907   $563,805 
           
Operating Losses:          
Aethlon  $(2,916,016)  $(2,156,769)
ESI   (382,442)   (703,411)
Total Operating Loss  $(3,298,458)  $(2,860,180)
           
Net Losses:          
Aethlon  $(3,318,853)  $(5,347,716)
ESI   (382,442)   (703,411)
Net Loss Before Non-Controlling Interests  $(3,701,295)  $(6,051,127)
           
Cash:          
Aethlon  $3,221,006   $2,446,820 
ESI   29,891    328,915 
Total Cash  $3,250,897   $2,775,735 
           
Total Assets:          
Aethlon  $3,514,098   $2,735,913 
ESI   78,765    420,582 
Total Assets  $3,592,863   $3,156,495 
           
Capital Expenditures:          
Aethlon  $9,307   $– 
ESI   –    – 
Capital Expenditures  $9,307   $– 
           
Depreciation and Amortization:          
Aethlon  $13,902   $13,328 
ESI   14,685    14,686 
Total Depreciation and Amortization  $28,587   $28,014 
           
Interest Expense:          
Aethlon  $(402,837)  $(293,522)
ESI   –    – 
Total Interest Expense  $(402,837)  $(293,522)